STOCK TITAN

Pediatrix officer plans sale of 9,260 shares

Pediatrix Medical Group, Inc. (MD) officer Mary Ann E. Moore filed a Rule 144 notice to sell 9,260 shares of common stock through Merrill Lynch on the NYSE, with an indicated aggregate market value of $246,365.53.

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Pediatrix Medical Group, Inc. (MD) officer Mary Ann E. Moore filed a Rule 144 notice to sell 9,260 shares of common stock through Merrill Lynch on the NYSE, with an indicated aggregate market value of $246,365.53. Shares outstanding were 81,253,271 as of the planned sale, a baseline figure, not the amount being sold.

Positive

  • None.

Negative

  • None.
Shares to be sold 9,260 shares Common stock to be sold under Rule 144
Aggregate market value $246,365.53 Market value of 9,260 shares covered by the notice
Shares outstanding 81,253,271 shares Common shares outstanding as of the planned sale date
Planned sale date August 14, 2026 Date for the Rule 144 sale on the NYSE
Stock award vesting (03/01/2022) 3,654 shares Common shares from vesting of a stock award, compensatory payment
Stock award vesting (03/01/2021) 3,042 shares Common shares from vesting of a stock award, compensatory payment
Earliest stock award vesting 200 shares Vesting of a stock award on August 10, 2010, compensatory payment
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Vesting of a Stock Award financial
"Common | 03/01/2022 | Vesting of a Stock Award | Pediatrix Medical"
Compensatory Payment financial
"3654 | 03/01/2022 | Compensatory Payment Common | 03/01/2021"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Pediatrix Medical Group (MD) disclose in this Form 144 filing?

The filing reports that officer Mary Ann E. Moore intends to sell 9,260 shares of Pediatrix Medical Group, Inc. common stock under Rule 144 through Merrill Lynch on the NYSE, with an indicated aggregate market value of $246,365.53.

How many Pediatrix Medical Group (MD) shares are planned to be sold under Rule 144?

Mary Ann E. Moore plans to sell 9,260 shares of Pediatrix Medical Group, Inc. common stock under Rule 144. These shares are expected to be sold through Merrill Lynch on the NYSE.

What is the approximate value of the shares in the Pediatrix Medical Group (MD) Form 144?

The 9,260 Pediatrix Medical Group, Inc. shares covered by the notice have an indicated aggregate market value of $246,365.53. This amount is based on the pricing information referenced in the Form 144 filing.

When is the planned sale date for the Pediatrix Medical Group (MD) shares?

The Form 144 states a planned sale date of August 14, 2026 for the 9,260 Pediatrix Medical Group, Inc. common shares to be sold under Rule 144 on the NYSE.

How many Pediatrix Medical Group (MD) shares were outstanding at the time of this Form 144?

The notice reports that 81,253,271 shares of Pediatrix Medical Group, Inc. common stock were outstanding as of the date referenced for the planned Rule 144 sale.

How were the Pediatrix Medical Group (MD) shares being sold originally acquired?

The 9,260 shares were acquired through vesting of stock awards and recorded as compensatory payments on several dates between 2010 and 2022, including awards vesting on March 1, 2022 and March 1, 2021.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading